A prospective trial to evaluate efficacy of natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis in the French follow-up cohort observatoire of multiple sclerosis.
Phase of Trial: Phase IV
Latest Information Update: 04 Feb 2016
At a glance
- Drugs Fingolimod (Primary) ; Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 04 Feb 2016 New trial record
- 29 Jan 2016 Retrospective analysis (n=629) published in the Neurology.